Trial · NCT01555892
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
NCT01555892, Phase 1, Recruiting, Baylor College of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE. Trials, record NCT01555892. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01555892
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT number
- NCT01555892
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 136 participants, estimated
- Lead sponsor
- Baylor College of Medicine
- Conditions
- Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Lymphoma
- Interventions
- EBV-specific T cells: A, EBV-specific T cells: B
- First posted
- 2012-03-16
- Last updated
- 2026-03-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of toxicity of escalating doses of LMP, BARF1 and EBNA1 T lymphocytes | 8 weeks | To determine the safety of escalating doses of 2 intravenous injections of autologous or syngeneic rapid LMP, BARF1 and EBNA1 specific T-lymphocytes (VSTs) in patients with EBV-associated Hodgkin's Disease or non-Hodgkin's lymphoma or T/NK-lymphoproliferative disease and CAEBV. |
| Secondary | Determine survival and immune function of LMP/BARF1/EBNA1-specific cytotoxic T-lymphocyte lines | 1 year | To determine the survival and the immune function of LMP/BARF1/EBNA1-specific cytotoxic T-lymphocyte lines |
| Secondary | Assess anti-viral and anti-tumor effects of LMP/BARF1/EBNA1-specific EBVST | 1 year | To assess the anti-viral and anti-tumor effects of LMP/BARF1/EBNA1-specific EBVST |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P50CA126752 | SPORE in Lymphoma | HESLOP, HELEN E; BRENNER, MALCOLM K. | BAYLOR COLLEGE OF MEDICINE | NATIONAL CANCER INSTITUTE | 2007 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01555892
GET https://conductscience.org/api/trials/v1/NCT01555892/registered